BCL2 and small cell lung carcinoma: While several groups have tried to gain mechanistic insights into various immunotoxin+Bcl-2 inhibitor anticancer therapies, only two studies [23, 33] have shown modest antitumor efficacy (improvement in survival by several days without cures), in in vivo subcutaneous small cell lung cancer and melanoma tumor models.